Prothena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director
(Thomson Reuters ONE) -
DUBLIN, Ireland, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
announced today that Gene Kinney, PhD has been appointed President and Chief
Executive Officer of Prothena. Dr. Kinney has also been appointed to Prothena's
Board of Directors. The appointments come following the passing of Prothena's
Co-founder, President and CEO, Dr. Dale B. Schenk on September 30, 2016.
"Gene is a well-known and highly respected biotechnology executive who is
uniquely qualified to lead Prothena," stated Lars G. Ekman, MD, PhD, Chairman of
the Prothena Board of Directors. "He has worked closely with Dale for many years
and leads an extremely experienced and talented team. While we share their
great sadness at the loss of our friend Dale, we are confident that the strategy
established by the Board of Directors and management team under Dale's
leadership will be advanced, and that the team will continue to work closely
with Prothena's employees, scientific collaborators and investors to forward the
mission of delivering meaningful therapeutics to treat devastating diseases."
"All of us at Prothena are extremely saddened by the loss of our co-founder and
friend Dale," stated Dr. Kinney. "Our team of incredibly talented employees will
work every day to honor Dale's memory through a continued commitment to our core
values of courage, creativity and selflessness; Dale embodied these values and
they drive our passion for developing important new therapies for patients.
Prothena was founded on Dale's clear and compelling vision of advancing new
medicines for dire and often untreatable diseases and we continue to be inspired
by, and find purpose in, this vision. We will always be profoundly grateful for
his friendship and leadership. Of course, during this time our thoughts are with
Dale's family and we will do everything we can to support them."
Dr. Kinney worked with Dr. Schenk since 2009, first at Elan and then at Prothena
when the Company spun out of Elan in 2012 as a preclinical stage company and has
since established itself as an integrated research, development and commercial
biotechnology company. As a founding member of Prothena's leadership team, Dr.
Kinney was Head of Research and Development and Chief Scientific Officer and led
the team responsible for advancing a robust pipeline into late-stage clinical
development as well as generating novel antibody targets in discovery. Dr.
Kinney was recently named Chief Operating Officer of Prothena and had been
leading the Company since Dr. Schenk began a medical leave of absence.
Prior to joining Prothena, in positions of increasing scope, Dr. Kinney has held
responsibility for overseeing portfolio strategy, leading R&D teams, and
supporting commercial product launches. Dr. Kinney was Senior Vice President of
Pharmacological Sciences at Elan Pharmaceuticals, Inc. and held several senior
R&D positions not only at Elan, but also Janssen Alzheimer Immunotherapy R&D,
Merck Research Laboratories and Bristol-Myers Squibb, and was an Assistant
Professor at the Emory University School of Medicine. Dr. Kinney earned his B.A.
from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic
University.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific
understanding built over decades of research in protein misfolding and cell
adhesion - the root causes of many serious or currently untreatable amyloid and
inflammatory diseases - Prothena is establishing a fully integrated research,
development and commercial focus and has advanced several drug candidates into
clinical studies while pursuing discovery of additional novel therapies. Our
pipeline of antibody-based product candidates targets a number of potential
indications including AL amyloidosis (NEOD001), Parkinson's disease and other
related synucleinopathies (PRX002), inflammatory diseases, including psoriasis
and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more
information, please visit the company's website at www.prothena.com.
Contacts:
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 03.10.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 498381
Anzahl Zeichen: 5403
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
